aibio
Listings ·
Windtree Therapeutics to be delisted by Nasdaq, shares move to OTC market
Nasdaq will suspend trading in Windtree's common stock at the open on August 21, 2025. The company has applied for the OTCID tier.
WINT Windtree Therapeutics, Inc.
Windtree Therapeutics (WINT) news WINT delisting news
Latest Windtree Therapeutics news
- Distress
Windtree Therapeutics files late notice for quarterly report for June 30, 2025
The company said it needs more time to finalize its financial statements and related disclosures. It expects to file within five calendar days after the due date.
- Financings
Windtree agrees to $60 million preferred stock sale to fund BNB treasury
Windtree agreed on July 16, 2025 to sell about 60,000 shares of Series E preferred stock with warrants, and to use the money to buy BNB. The deal cannot close until shareholders approve it, and it lapses if approval is not obtained within 120 days.
Windtree Therapeutics annual financials
| Line | FY2024 | FY2023 |
|---|---|---|
| Research and development | $16.3 million | $8.3 million |
| Net income (loss) | -$1.8 million | -$20.3 million |
| Cash from operations | -$15.4 million | -$13.4 million |
| Cash and equivalents | $1.8 million | $4.3 million |
Questions about Windtree Therapeutics
Was Windtree Therapeutics delisted?
Our latest story on this, dated Aug 20, 2025: "Windtree Therapeutics to be delisted by Nasdaq, shares move to OTC market". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Windtree Therapeutics?
Windtree Therapeutics, Inc. trades under the ticker WINT on OTC.
Where is Windtree Therapeutics listed?
Windtree Therapeutics, Inc. is listed on OTC.
What is the SEC CIK of Windtree Therapeutics?
The SEC Central Index Key (CIK) for Windtree Therapeutics, Inc. is 946486. Its filings are on SEC EDGAR.
How many shares does Windtree Therapeutics have outstanding?
33,708,784 shares as of 2025-11-14, per the cover page of its 10-Q filed 2025-11-19.
Which country or territory is Windtree Therapeutics listed under?
Our directory records Windtree Therapeutics, Inc. under United States.
What does Windtree Therapeutics do?
Our directory classifies Windtree Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Windtree Therapeutics?
The ISIN recorded for Windtree Therapeutics, Inc. is US97382D6004.
Does aibio.space cover Windtree Therapeutics?
aibio.space lists Windtree Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Windtree Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Windtree Therapeutics profitable?
Windtree Therapeutics, Inc. reported a net loss of $1.8 million for the fiscal year ended Dec 31, 2024, and used $15.4 million of cash in operations, per its annual report to the SEC.
How much does Windtree Therapeutics spend on research and development?
$16.3 million in the fiscal year ended Dec 31, 2024, per its annual report.
How much cash does Windtree Therapeutics have?
$204,000 in cash at Sep 30, 2025, per its 10-Q.
What is the latest Windtree Therapeutics (WINT) stock news?
Our latest story on Windtree Therapeutics, dated Aug 20, 2025: "Windtree Therapeutics to be delisted by Nasdaq, shares move to OTC market". Nasdaq will suspend trading in Windtree's common stock at the open on August 21, 2025. The company has applied for the OTCID tier. Source.
What is Windtree Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Jul 17, 2025: "Windtree agrees to $60 million preferred stock sale to fund BNB treasury". Windtree agreed on July 16, 2025 to sell about 60,000 shares of Series E preferred stock with warrants, and to use the money to buy BNB. The deal cannot close until shareholders approve it, and it lapses if approval is not obtained within 120 days. Source.
Investor discussion: Windtree Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Stock chart
SEC filings and registration
- SEC name
- Windtree Therapeutics Inc /De/
- CIK
- 946486
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- WINT (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2600 KELLY ROAD, WARRINGTON, PA, 18976
- Phone
- 2154889300
- Shares outstanding
- 33,708,784 as of 2025-11-14 (10-Q filed 2025-11-19)
- Former names
- DISCOVERY LABORATORIES INC /DE/; ANSAN PHARMACEUTICALS INC; ANSAN INC
Recent filings
Listing details
- Company
- Windtree Therapeutics, Inc.
- Ticker
- WINT
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US97382D6004
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction